MX345019B - Nuevo anticuerpo ctgf antihumano. - Google Patents
Nuevo anticuerpo ctgf antihumano.Info
- Publication number
- MX345019B MX345019B MX2014007681A MX2014007681A MX345019B MX 345019 B MX345019 B MX 345019B MX 2014007681 A MX2014007681 A MX 2014007681A MX 2014007681 A MX2014007681 A MX 2014007681A MX 345019 B MX345019 B MX 345019B
- Authority
- MX
- Mexico
- Prior art keywords
- human ctgf
- ctgf antibody
- seq
- amino acid
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un anticuerpo CTGF antihumano que tiene una actividad de unión superior y/o una actividad neutralizante superior en comparación con aquella de los anticuerpos CTGF antihumanos convencionales; y un medio para prevenir o tratar varias enfermedades en las que el CTGF humano está implicado en la formación de condiciones clínicas de los mismos, que incluye las enfermedades renales como la enfermedad renal crónica y la nefropatía diabética, al usar el anticuerpo CTGF antihumano mencionado. Un anticuerpo CTGF antihumano que contiene una región variable de cadena pesada que comprende la secuencia de aminoácidos representada por la SEC ID NO: 10 y una región variable de cadena ligera que comprende la secuencia de aminoácidos representada por SEC ID NO: 4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011281811 | 2011-12-22 | ||
| PCT/JP2012/083206 WO2013094723A1 (ja) | 2011-12-22 | 2012-12-21 | 新規抗ヒトｃｔｇｆ抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014007681A MX2014007681A (es) | 2014-11-25 |
| MX345019B true MX345019B (es) | 2017-01-11 |
Family
ID=48668601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014007681A MX345019B (es) | 2011-12-22 | 2012-12-21 | Nuevo anticuerpo ctgf antihumano. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9587015B2 (es) |
| EP (1) | EP2796550B1 (es) |
| JP (1) | JP6040943B2 (es) |
| KR (1) | KR20140107507A (es) |
| CN (1) | CN104011206B (es) |
| AR (1) | AR089425A1 (es) |
| BR (1) | BR112014015405A2 (es) |
| CA (1) | CA2859627A1 (es) |
| EA (1) | EA029290B1 (es) |
| ES (1) | ES2665851T3 (es) |
| IN (1) | IN2014CN04615A (es) |
| MX (1) | MX345019B (es) |
| PL (1) | PL2796550T3 (es) |
| PT (1) | PT2796550T (es) |
| TW (1) | TW201333034A (es) |
| WO (1) | WO2013094723A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109824777A (zh) * | 2019-03-15 | 2019-05-31 | 辽宁何氏医学院 | 一种具有抑制玻璃体视网膜纤维化病变作用的单克隆抗体及其制备方法和应用 |
| US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
| CA3142092A1 (en) * | 2019-06-04 | 2020-12-10 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-connective tissue growth factor antibody and application thereof |
| MX2023006383A (es) * | 2020-12-03 | 2023-06-14 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composicion farmaceutica que contiene anticuerpo anti-factor de crecimiento de tejido conjuntivo. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8808645U1 (de) | 1988-07-06 | 1988-08-25 | Hofer, Daniel, 7730 Villingen-Schwenningen | Anzeigeeinrichtung für Feuerlöscher |
| US6114143A (en) | 1993-03-11 | 2000-09-05 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Anti-HIV monoclonal antibody |
| JP4537507B2 (ja) * | 1997-12-25 | 2010-09-01 | アムジェン インコーポレイテッド | 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途 |
| US6562618B1 (en) | 1997-12-25 | 2003-05-13 | Japan Tobacco, Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| US7115390B1 (en) | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| WO2000035939A2 (en) * | 1998-12-14 | 2000-06-22 | University Of Miami | Connective tissue growth factor fragments and methods and uses thereof |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| JP2009067678A (ja) * | 2005-12-07 | 2009-04-02 | Nihon Nosan Kogyo Kk | 結合組織増殖因子に対する抗体又はそれを含む組成物 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
-
2012
- 2012-12-21 MX MX2014007681A patent/MX345019B/es active IP Right Grant
- 2012-12-21 PT PT128607421T patent/PT2796550T/pt unknown
- 2012-12-21 CN CN201280063995.5A patent/CN104011206B/zh active Active
- 2012-12-21 CA CA2859627A patent/CA2859627A1/en not_active Abandoned
- 2012-12-21 IN IN4615CHN2014 patent/IN2014CN04615A/en unknown
- 2012-12-21 JP JP2013550349A patent/JP6040943B2/ja active Active
- 2012-12-21 WO PCT/JP2012/083206 patent/WO2013094723A1/ja active Application Filing
- 2012-12-21 AR ARP120104933A patent/AR089425A1/es unknown
- 2012-12-21 US US14/367,081 patent/US9587015B2/en active Active
- 2012-12-21 TW TW101148989A patent/TW201333034A/zh unknown
- 2012-12-21 KR KR1020147020039A patent/KR20140107507A/ko active IP Right Grant
- 2012-12-21 BR BR112014015405A patent/BR112014015405A2/pt unknown
- 2012-12-21 PL PL12860742T patent/PL2796550T3/pl unknown
- 2012-12-21 EA EA201491240A patent/EA029290B1/ru not_active IP Right Cessation
- 2012-12-21 ES ES12860742.1T patent/ES2665851T3/es active Active
- 2012-12-21 EP EP12860742.1A patent/EP2796550B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2859627A1 (en) | 2013-06-27 |
| ES2665851T3 (es) | 2018-04-27 |
| JP6040943B2 (ja) | 2016-12-07 |
| EP2796550A4 (en) | 2015-08-19 |
| EA201491240A1 (ru) | 2014-11-28 |
| EA029290B1 (ru) | 2018-03-30 |
| PL2796550T3 (pl) | 2018-08-31 |
| AR089425A1 (es) | 2014-08-20 |
| PT2796550T (pt) | 2018-04-18 |
| CN104011206A (zh) | 2014-08-27 |
| MX2014007681A (es) | 2014-11-25 |
| JPWO2013094723A1 (ja) | 2015-04-27 |
| IN2014CN04615A (es) | 2015-09-18 |
| US20140343258A1 (en) | 2014-11-20 |
| CN104011206B (zh) | 2017-03-08 |
| US9587015B2 (en) | 2017-03-07 |
| TW201333034A (zh) | 2013-08-16 |
| EP2796550B1 (en) | 2018-02-28 |
| KR20140107507A (ko) | 2014-09-04 |
| EP2796550A1 (en) | 2014-10-29 |
| BR112014015405A2 (pt) | 2017-06-13 |
| WO2013094723A1 (ja) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| RU2013140625A (ru) | Антитела против ангиопоэтина-2 человека | |
| BR112014002613A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método | |
| WO2013011076A3 (en) | Tnf -alpha antigen- binding proteins with increased fcrn binding | |
| NZ705848A (en) | Anti-cd38 antibodies | |
| WO2009048537A3 (en) | Humanized antibody | |
| NZ706986A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| MX2014001627A (es) | Nuevo anticuerpo anti-ngf humano. | |
| UA112743C2 (uk) | Терапевтичний dll4-зв'язувальний білок | |
| EA201500132A1 (ru) | Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| MX2010009190A (es) | Anticuerpos anti-c5ar humanizados. | |
| WO2013120012A3 (en) | Cdim binding proteins and uses thereof | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| WO2009048538A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
| EA201290849A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| EP2548574A4 (en) | NEW HUMANIZED MONOCLONAL ANTIBODY ANTI-CD20 | |
| WO2013013025A3 (en) | Anti-cxcr4 antibodies and methods of use | |
| NZ603191A (en) | Methods for the treatment of il-1b related conditions | |
| MX345019B (es) | Nuevo anticuerpo ctgf antihumano. | |
| JO3188B1 (ar) | بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل | |
| WO2014028668A3 (en) | Stem cell enhancing therapeutics | |
| EA201492162A1 (ru) | Антитела к трансглютаминазе 2 | |
| BR112014008331A2 (pt) | anticorpos sema4a anti-humanos úteis para tratar doença | |
| BR112013021860A2 (pt) | anticorpo anti-tnfalpha humanizado |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |